Member Info for Paul2566

Phatyoda
Yes that is what I meant. I wasn't trying to be negative.
I'm actually weighing up buying some more stock at these prices, but my sensible head keeps telling me to wait.
However if it drops much lower with no negative news, then the risk/reward starts to balance out again.

The point I make is that its neutral.
No value added, no potential added. No loss, no gain, and of course not negative.
Spinning no news into news is pointless.

People really need to explore a RNS.
Director of MXC Evan Hayes aquired 295000 ordinary shares. Value $17,655.75. Its unclear if its US or AUS dollars.
However if we convert 295000 shares at 3p which would have been the ballpark stock bid price it equates to £8850.

I can't determine if the stock was purchased by Mr Hayes, which I doubt, or it was part of a package recieved from MXC as part of his contract. In any case it is such a small sum I doubt it was based on insider knowledge which would offer MXC any benifit.

As for following the money, trades so far today don't show any interest of note. Only a handful of trades of 100,000 shares or more, with the largest being a sell of circa £15000, and a similar value buy. The remaining trades are nickle and dime values.

Nothing of note in this RNS, although personally I remain bullish on this stock, but wont increase my holding until further positive news becomes available.

I think MXC is 'doing something', but results take years to achieve.

I'm afraid he's not really a public speaker, and has little personality that comes through on camera. If you are going to read verbatim from notes, at least place them somewhere near the camera so its not so obvious, but he really should know this stuff, with a only few prompt notes to keep him on track.
It needs a PR front person to sell it.
I watched his whole presentation live and it actually reduced my confidence in the company management.

Gazzleberry
I share your views, I may be tempted to sell at 3.2, with a view to buy back around 3, but it could mean missing out.
I think I'll just wait and see for now.

Well nothing in the report that brings me any surprises.
I would like an indication of how they intend to raise further funding.
I think loans would be available based on the companies progress over the last 12 months, but I doubt they would be available at discounted rates, and with the liklyhood of interest rate rises a very real threat I'm not convinced this would be the best way to raise capital at the moment.
Issuing further shares looks to me to be the best and most likly option, but this has its own issues. I doubt a further share issue would do much for investor sentiment, and of course it would require quite a large volume of investors willing to put further funds into the stock.
The AMC US deal once enacted would go a long way to helping both options.
Of course I think MXC is quite vulnerable at the moment to an aquisition, if a pharma company believes in an impending turnaround, they could I think get MXC relatively cheaply, selling off assets not required and keeping the core buisness and its licences.
We will certainly know the answer within the next few months, and probably within this calender year.

Its just the end of year financial report.

quangy
I do it every year by phone, they just want the total gains for div tax, keep it simple, if they want more info let them ask for it.

quangy
If you look on the Gov website it will give guidance and telephone numbers. I can't remember the exact details but for relatively small amounts you can report over the phone with a 5 minute call. I guess its just not worth the time it takes for them to get involved.

wezpop
Don't forget, your wife can also have an ISA thats £40000 PA, plus she also has the same £12500 CGT and £2000 dividend allowance outside the ISA. With a bit of perfectly legal juggling much of the tax burden can be greatly reduced.

No CGT on first £12500, but remember that all sources, except those stocks held in an ISA, and of course gold if its in legal tender.
Dividends, first £2000 free from tax, after that unless in an ISA tax is due, usually just a phone call to report gains sometime after 6th April.
I have filled both the wifes and my ISA for the last couple of years and hold the rest of my portfolio in a trading account, which I treat as a BED. I can't really avoid tax on the dividends, but with some care I can sell stock in the BED and buy back in the ISA each year and avoid CGT.

casapinos
Pretty good guess, December 2020 debt stood at £4.875 billion, but when typed out in full £4,875,000,000 its quite a lot, and yes its in GBP not US dollars. I can state with a high degree of certainty it hasn't decreased since then. So getting that down must be a priority for the board I would imagine.

I apologise Phatyoda, bad mood this morning, just getting fed up with stupid posts.
No excuse for bad manners.
Sorry.

Back into the 1.44s.
Botbot I think RR will use the cash from the sale to pay down some of the debt.
I can see debt as getting expensive over the next couple of years and suspect RR will wish to reduce it as much as possible.
The lenders would also seem to share this view as its a caveat on at least one of the loans that no dividend be paid prior to 2023.

I think some are missing the point.
This is most likly just part of the AMC deal released in an RNS dated 26th August 2021, concerning a deal worth US $3m in year 1 (providing the imported AMC can obtain a National Clinical Trial Number), followed by a further US $21m over years 2 and 3.
In essence the RNS being discussed is a non news event, and is hardly 'a ground breaking RNS'.
MXC is going to provide me with a reasonable profit over the next 5 years, but lets try and leave the hype ans BS out.

I believe this is just part of the potential AMC deal, which we may hear more about tomorrow. The AMC deal was released in an earlier RNS dated 26th August 2021. The AMC deal is potentially worth US $ 24m.
The Amc deal extends over 3 years and relys on the grant of a National Clinical Trial Number, which if not aquired kills the deal, although I see no reason why a National Clinical Trial numbe will not be issued.
The first year deal would be for US $3m, with the remaining US $21 being spread over years 2 and 3.

In essence its a non news event and hardly a 'ground breaking RNS', and dosen't indicate any liklyhood of an increase in orders over those already disclosed in the AMC related RNS.

I believe that MXC is going to provide me with good returns over the next 5 years, but lets try and avoid the hype nonsense and keep it somewhere near reality.

Not before 2023 at the earliest.

I think thats about it for now, everyone who wanted in has probably already jumped on board.
It might drop 1p or 2p tomorrow at times as some decide to take profits.
Hopefully after a little up and down will finish the week in the 1.45 to 1.50 range.
I would expect further small moves up as flight time increases.
Of course further positive news may send it on its way again.
It can't go up every day after all.
I would imagine those that stay the course will see a tidy return over the next 5 years.
Remember 'Time in the market tends to beat timing the market'

Unlikly
I'll be happy if it holds above 1.46.
It would be a good base for a gentle upward drift.

Paul1828

1828 collar number?